Status: Finalised
First registered on:
17/11/2010
Last updated on:
28/11/2013
1. Study identification
EU PAS Register NumberEUPAS1705
Official titleA/H1N1 pandemic vaccines and pregnancy outcomes
Study title acronym
Study typeObservational study
Brief description of the study1) identification of relevant research centres, organisations and agencies active in the evaluation and safety of A/H1N1 vaccine safety in pregnant women;
2) organise and coordinate an exchange of information between these centres, organisations and agencies with the aim to conduct a meta analysis of study results where appropriate;
3) In collaboration with all stakeholders, produce a proposal for a long-term collaboration between research centres active in the field of drugs and pregnancy outcomes, including interaction with ENCePP; this deliverable will involve extending the profile of centres included in the inventory mentioned under 1)
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research group
Organisation/affiliation
Details of (Primary) lead investigator
Title Professor
Last name de Vries
First name Corinne
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?2
Countries in which this study is being conducted
International study
Denmark
Finland
Germany
Italy
Netherlands
Sweden
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed19/10/201019/10/2010
Start date of data collection19/10/201026/10/2010
Start date of data analysis30/11/2012
Date of interim report, if expected19/07/2011
Date of final study report30/06/201331/01/2013
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding scheme
OtherEMA100
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name de Vries
First name Corinne
Address line 1Department of Pharmacy & Pharmacology
Address line 2University of Bath
Address line 3Claverton Down
CityBath
PostcodeBA2 7AY
CountryUnited Kingdom
Phone number (incl. country code)441225384228
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name de Vries
First name Corinne
Address line 1Department of Pharmacy & Pharmacology
Address line 2University of Bath
Address line 3Claverton Down
CityBath
PostcodeBA2 7AY
CountryUnited Kingdom
Phone number (incl. country code)441225384228
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Single-Constituent (Substance INN)INFLUENZA VIRUS, TYPE A, H1N1 7.0 LOG 10 FFU (FLUORESCENT FOCUS UNITS) PER DOSE
7. Medical conditions to be studied
Medical condition(s)Yes
Drug exposure during pregnancy
8. Population under study
Age
Preterm newborns
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Sex
Male
Female
Other population
Pregnant women
9. Number of subjects
Estimated total number of subjects2
Additional information
very difficult to estimate numbers; it all depends on willingness of centres to contribute data for the meta analysis plus whether meta analysis or pooling of data is appropriate.
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Prospective patient-based data collection
Disease/case registry
Administrative database, e.g. claims database
Exposure registry
Pharmacy dispensing records
Case-control surveillance database
11. Scope of the study
What is the scope of the study?
Risk assessment
setting up a network for drug safety in pregnancy evaluation
Primary scope : Risk assessment
12. Main objective(s)
What is the main objective of the study?
to identify all studies of H1N1 vaccine safety in pregnancy, to conduct meta analyses of the studies identified as appropriate, and to set up a network for evaluation of drug safety in pregnancy.
Are there primary outcomes?Yes
1) inventory of studies; 2) quantification of adverse pregnancy outcomes; 3) establishment of network
Are there secondary outcomes?No
13. Study design
What is the design of the study?
meta analysis
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
We will establish whether it is appropriate to pool the data and to analyse the pooled data where appropriate. Heterogeneity in study results between participating centres will be identified, evaluated, and where necessary we will go back to the data suppliers for any additional verification exercises required. When appropriate, a pooled analysis will be carried out.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Not submitted
18. Study Results
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documents
DescriptionDocumentLatest version
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
